Rosuvastatin calcium (ROS), (Figure 1 ) belongs to the "statins" group, which is the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. This drug is indicated for dyslipidemias treatment and can help to decrease the level of "bad cholesterol" and can consequently reduce the development of atherosclerosis and the risk of heart diseases. ROS was developed by Astra-Zeneca and it was approved in 2003 by the FDA in the United States. In 2015, under the trade name Crestor Ò , it was the fourth largest selling drug in the United States with sales above $5 billion. This study presents a literature review of analytical methods for the quantification of ROS in pharmaceutical preparations and biological fluids. The major analytical methods described in this study for ROS were spectrophotometry, highperformance liquid chromatography (HPLC) coupled to ultraviolet (UV) detection, and tandem mass spectrometry (LC-MS/MS).
Introduction
Rosuvastatin calcium (ROS) is a member of a class of cholesterol-lowering medications commonly referred to as "statins," which was developed by Pharmaceutical Company AstraZeneca, and it was approved in the United States in 2003. [1] Statins specifically inhibit the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which converts HMG-CoA into mevalonic acid. HMG-CoA reductase is a rate-limiting step in the biosynthesis of cholesterol. [2] Several statins, also called HMG-CoA reductase inhibitors, are commercially available in the market: Lipitor Ò (atorvastatin), Lescol Ò (fluvastatin), Mevacor Ò (lovastatin), Livalo Ò (pitavastatin), Pravachol Ò (pravastatin), Crestor Ò (rosuvastatin), and Zocor Ò (simvastatin). The statins are highly effective drugs in reductions in low-density lipoprotein cholesterol (LDL-C) levels. [3] LDL-C is a primary atherogenic lipoprotein. Several clinical trials have shown the benefit of statin therapy in primary prevention of cardiovascular events due to the cholesterol reduction. [4] [5] [6] Larger reductions in LDL-C levels are related with reductions in cardiovascular events, and within the statin class, ROS is responsible for the greatest reduction on LDL-C levels. [7, 3] Nowadays, there is an emerging interest in the application of statins in cancer treatment, since high levels of mevalonic acid production are observed in various types of malignancies, such as breast cancer, [8] leukemia, [9] lymphoma, [10] and prostate carcinoma cells. [11] [12] [13] The development of analytical methods for the quantification of statins in biological fluids is a key determinant in pharmacokinetics and drug-drug interactions studies. The clinical importance of the cytochrome P450 (CYP) enzymes and drug transporters has become apparent, mainly in the context of drug-drug interactions. [14] The HMG-CoA reductase inhibitor, cerivastatin, was withdrawn from the market in August 2001 due the severe rhabdomyolysis produced during coadministration of gemfibrozil and cerivastatin. A metabolite of gemfibrozil inhibits CYP2C8-mediated metabolism of cerivastatin and greatly increases plasma concentrations of cerivastatin. [15] The organic anion transporting polypeptide (OATP1B1) facilitates the hepatic uptake of most statins, mainly pravastatin and rosuvastatin. Interference with the function of this hepatic uptake transporter, as the co-administration with inhibitors (e.g., cyclosporine A) or genetic polymorphisms, could decrease the efficacy and safety of the statins. [16] In this context, it is important to use well-characterized and fully validated analytical methods to yield reliable pharmacokinetic data. Several analytical methods have been developed for the quantitation of each HMG-CoA reductase inhibitor also in pharmaceutical formulations that are crucial during quality control process of pharmaceutical products. Furthermore, analytical methods for the quantification of mevalonate acid have been developed in order to be used as a biomarker for the enzyme inhibition by statins. [17] [18] [19] [20] Despite reviews about quantitation of statins in pharmaceutical formulations and biological samples have been previously published, none of these reviews focused on ROS analytical methods, perhaps because it is one of the latest statins introduced in the market. [21] [22] [23] The aim of this review is to provide an overview of relevant published literature and a discussion of methods for the determination of ROS on its own or in mixtures, in pure form, formulations, and biological samples using different analytical procedures (HPLC-UV, LC-MS/MS, spectrophotometry, etc.).
Rosuvastatin
Chemistry ROS is a synthetic compound produced as monocalcium bis (C)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylN-methansulfonylaminopyrimidine)-5-yl)-(3R, 5S)-dihydroxy-(E)-6-heptenoate. [24, 25] The configuration of ROS consists of a single enantiomer (3R, 5S), formulated and administrated as a calcium salt of the active hydroxy acid. [26] The chemical formula is C 44 H 54 CaF 2 N 6 O 12 S 2 and molecular weight is 1001.141 g/mol (Crestor Ò , U.S. approved label). ROS is a white amorphous powder that is sparingly soluble in water and methanol (MeOH), and slightly soluble in ethanol (EtOH). [25, 27] The pharmacophore constitutes of a dihydroxy heptenoic acid portion, which binds to the active site of the target enzyme HMGCoA reductase. [2] Differently from other statins, the addition of a stable polar methane sulfonamide group in the ROS structure confers relatively low lipophilicity. [28, 29] The log D (distribution of the drug into octanol:water) measured at pH 7.4 is ¡0.33, which is comparable to pravastatin and lower than other statins (atorvastatin, fluvastatin, simvastatin, and cerivastatin). [29] The commercial formulations of ROS tablets available contain 5, 10, 20, or 40 mg of ROS. [27] Pharmacodynamics, efficacy, and safety ROS produces beneficial effects on the lipid profile by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, a limiting enzyme in cholesterol biosynthesis that converts HMG-CoA to mevalonate. ROS is a competitive inhibitor of HMG-CoA reductase, presenting a chemical structure very similar to HMG portion of HMG-CoA. Olsson et al. [30] have reported that a dosage of ROS from 1 to 80 mg over 6 weeks has resulted in LDL-C reductions ranging from 34% to 65%. Some clinical trials have demonstrated the effectiveness of ROS compared to other statins on the reduction of LDL-C. [31] [32] [33] The STELLAR study showed the greatest efficacy of ROS in improving LDL-C, triglycerides, and HDL-C levels. It is considered the most effective statin in increasing HDL-C, ranging from C7.7% to C9.6% compared to C2.1% to C6.8% with other statins (atorvastatin, pravastatin, and simvastatin). [33] In this same study, it was observed that ROS dosage of 10-80 mg has reduced LDL-C 8.2% more than atorvastatin dosage of 10-80 mg, 26% more than pravastatin dosage of 10-40 mg, and 12-18% more than simvastatin dosage of 10-80 mg. [33] Most of the lipid therapies are aimed at achieving treatment goals from guideline bodies. ROS enabled a greater proportion of treated patients to National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) and European LDL cholesterol goal. [33] ROS can be associated with other drugs in order to improve the management of high-risk patients who cannot reach the cholesterol goal on maximal ROS dose monotherapy. A significant number of patients taking ROS/ezetimibe instead of ROS on its own achieved their NCEP ATP III cholesterol goal (<100 mg/dL, 94.0% versus 79.1%, respectively, p < 0.001). [34] The incidence of adverse events during ROS 10-40 mg daily therapy is comparable to those of other statins. [35] In a clinical evaluation with 2579 patients taking ROS, myalgia was reported in 5.1% of patients and the creatine kinase elevation was reported in 2.1% of the patients. [36] The myopathy (creatine kinase increasing 10-fold the upper limit of normal plus muscle symptoms) was 0.2% and all cases occurred in patients using high doses. [36] A safety study detected the incidence of adverse effects per 10,000 patients taking ROS; the incidence of myopathy was 0.4, of rhabdomyolysis was 0.4, and of acute liver injury was 0.4 per 10,000 person-years. [37] The dose range indicated in the U.S. label of ROS (Crestor Ò , Astra Zeneca) is 5-40 mg daily, and 40 mg is not indicated for initial therapy but is for patients that did not reach LDL-C goal with 20 mg. [27] 
Pharmacokinetics
The oral bioavailability of ROS is approximately 20% and the peak plasma concentration (C max ) is reached 3-5 hours after administration of 10-80 mg oral dose. C max and area under the plasma concentration-time curve (AUC) increase proportionally to the dose. Administration of ROS with food decreased the rate of drug absorption by 20% as assessed by C max ; however, the extent of absorption is not affected when assessed by AUC. [27] The mean volume of distribution at steady state of ROS is approximately 134 L. ROS is 88% bound to plasma proteins, mainly albumin. ROS undergoes minimal metabolism with approximately 10% of radio-labeled dose recovered as metabolite. [27] In vitro studies with cultured human hepatocytes showed an extremely slow metabolism with a single abundant metabolite, N-desmethyl ROS. Cytochrome 2C9 (CYP2C9) was the primary isoenzyme involved with minor contributions of CYP2C19 and CYP3A4. [38] The evidence of the limited role of metabolism in the ROS clearance is supported by drug-interaction trials employing common CYP inhibitors. Co-administration of the CYP3A4 inhibitor ketoconazole did not produce meaningful changes in ROS exposure. [39] Co-administration of a potent CYP2C9 inhibitor, fluconazole, produced only a slight increase in the systemic exposure of ROS. [40] Recovery of ROS is primarily via fecal route of elimination with approximately 72% of absorbed ROS eliminated via bile secretion and 28% via renal excretion. The circulating plasma half-life is approximately 20 hours. [40] No effects on the pharmacokinetics of ROS have been observed regarding age, sex, or time of day of administration (morning or evening). [41, 42] Nevertheless, metabolic ethnic differences play an important role in ROS disposition. The organic anion transporting polypeptide C (OATP1B1) is expressed in the basolateral membrane of hepatocytes and contributes to hepatic uptake of ROS. [43] Several single-nucleotide polymorphisms (SNPs) in the gene encoding OATP1B1 (SLCO1B1) have already been described. Some of these SNPs, as OATP1B1 521C, show reduced function on the transporter. The frequency of OATP1B1 521C has been reported as 11-16% in Japanese patients and 8-16% in other Asians backgrounds. [44, 45] It was observed an increase in plasma exposure of ROS in Asian population when compared with Caucasian patients (AUC 0-t 86% and 55% higher for ROS in Chinese and Japanese population, respectively). [46] Due this issue, in the United States, the recommended initial dose of ROS for Asians is 5 mg, which is half of the dose recommended for Caucasians. [47] Analytical methods
The development of analytical methods for the analysis of ROS in different matrices is very relevant, mainly to assist bioavailability, bioequivalence, and pharmacokinetic studies as well as monitoring the quality of the marketed product. HPLC coupled to UV or tandem mass spectrometry is the most used method for qualitative and quantitative analysis of ROS alone or in mixtures. UV-Visible Spectrophotometer was employed mainly in pure form and pharmaceutical formulations analysis. Other methods, such as capillary electrophoresis, fluorimetric methods (HPLC or spectrophotometry), thin-layer chromatography (TLC), and electrodes, were less used.
Spectrophotometric methods with UV-Visible detection have been developed for ROS analysis alone and in simultaneous determination as presented in Table 1 . [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] The matrices most employed in the studies were standard and pharmaceutical formulations, except for the spectrofluorimetric method developed by Braga et al. [53] , which analyzed ROS in urine samples. The solvent most employed in spectrophotometric method was methanol (MeOH). Derivative spectrophotometric determination of ROS was performed with the respective reagents and wavelength detection: safranin at 530 nm, methylene blue at 655 nm, iodine at 291 and 360 nm, quinalizarin at 579 nm, and bromocresol green at 416 nm. [50] [51] [52] 54] Spectrophotometric methods were developed for the estimation of ROS combined with fenofibrate in dosage formulations. [57, 59, 61, 62] Considering the analysis of ROS in combination or alone, the linearity was observed in concentrations from 0.48 mg/mL to 500 mg/mL, nevertheless, in most cases, the typical range was around 1-10 mg/mL.
There are plenty of analytical methods employing HPLC with UV detection for ROS determination in pharmaceutical formulations and biological fluids. Tables 2 [25, 56, [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] and 3 [61, show the reported HPLC methods developed for ROS analysis alone and in combination with other drugs, respectively. In general, HPLC-UV methods employed C18 analytical columns. The wavelength used in HPLC-UV methods ranged between 215 and 275 nm, in general it was set to 242 nm. The mobile phase commonly employed was MeOH and/or acetonitrile (ACN) as organic solvent and water or buffer with pH adjusted to 3.0. Since ROS is an acidic compound (pka D 4.6), its retention time in the analytical column is likely to be pH dependent and lowering pH keeps ROS in its non-ionized form. The retention time observed in the main HPLC-UV methods revised was relatively short varying from 1.52 minutes to 6.7 minutes; however, some other methods presented longer retention times around 13 minutes. Extensive retention time of ROS was demonstrated in two methods developed by Kishore et al. [79] (24.6 minutes) and Pasha et al. [92] (33.5 minutes). More sensitive methods have been developed using HPLC-UV when compared with a UV-visible spectrophotometer. The most sensitive bioanalytical methods showed lower concentration on the linearity curve from 0.01 mg/mL to 0.03 mg/mL, except for the method developed by Nasir et al. [96] that was more sensitive with the value of 2 ng/mL. However, other analytical and bioanalytical methods demonstrated higher sensitivity values ranging from 0.05 mg/mL to 30 mg/ mL. Table 4 [56, [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] shows the LC-MS/MS methods developed for ROS analysis alone or in combination with other drugs determined in biological fluids. Most LC-MS/MS analyses were performed in positive ion mode (ESI C ) for the quantification of ROS in human plasma. LC-MS/MS methods were performed with a C18 analytical column and the mobile phase was composed by MeOH or ACN as organic solvent and water with volatile additives including ammonium acetate and formic acid, which were added in order to enhance ionization and to get higher sensitivity of the method. The most employed method was multiple reaction monitoring (MRM) and the precursor [109] Retention times were very short, including methods for simultaneous analysis with other drugs, ranging from 0.9 minutes up to 4.1 minutes. Isocratic elution was applied in most cases. More sensitive methods have been developed using LC-MS/MS when compared with HPLC-UV with linearity ranging from 0.02 ng/mL to 512 ng/mL. UPLC is a separation category that uses sub-2-mm porous particles and decreases analysis time and solvent consumption when compared with the conventional LC methods [125] [126] [127] [128] Despite the advantages, there were a few UPLC methods developed to estimate ROS in pharmaceutical forms [72, 107] and biological samples. [125] It is useful for the development of analytical methods for simultaneous determination of ROS and other drugs used during the treatment of hyperlipidemic patients. For instance, ezetimibe is a drug used in association with ROS due the greater LDL-C reduction compared with ROS alone. [34] A method using LC-MS/MS equipped with an ESI interface and operated in negative ionization mode was employed with this aim contrast to the most usual method that uses positive ionization mode for ROS detection. [122] Other simultaneous analyses with lipid-lowering drugs were performed with fenofibric acid in human plasma using LC-MS/MS [119] and in bulk and tablets using HPLC detection. [61] Gemfibrozil was analyzed simultaneously with ROS in human plasma samples employing the HPLC-UV method. [81] Sharma et al. [62] and Ashfaq et al. [90] have proposed HPLC methods for the quantification of ROS with fenofibrate in tablets and ezetimibe in human plasma, respectively. Spectrophotometric methods were developed for simultaneous determination of ROS and fenofibrate in tablets, [57, 59, 61, 62] since these drugs are associated in the same dosage form, for example, tablets with 10 mg of ROS and 80 mg of fenofibrate. ROS is commonly associated with antihypertensive drugs, since high-serum cholesterol has been frequently reported in patients with arterial hypertension. In this context, a simultaneous method for ROS and lisinopril, captopril, and enalapril analysis in pharmaceutical dosage and human serum was developed using HPLC. [83] Simultaneous determination of amlodipine and ROS in human plasma was performed using LC-MS/MS with a linear range of 0.52-51.77 ng/mL for ROS. [118] There are a few works that describe the determination of a number of statin structures simultaneously, probably because statins are not used with other statins concurrently during the treatment of hyperlipidemic patients. A method was developed for simultaneous determination of atorvastatin, lovastatin, pravastatin, ROS, and simvastatin in pharmaceutical formulations and in vitro metabolism samples using HPLC. [92] The method employed a C18 column and mobile phase comprising 0.01 M ammonium acetate (pH 5.0), ACN, and MeOH. The chromatography run was delayed with the last analyte (ROS) eluting at 35.5 minutes. [79] Gomes et al. [82] proposed a short chromatographic run of simultaneous estimation of fluvastatin, atorvastatin, pitavastatin, and ROS in tablets using the HPLC method. The retention time for ROS was 4.18 minutes and the last analyte eluted at 4.95 minutes. Recently, Kosek et al. [121] reported a sensitive LC-MS/MS method for simultaneous quantitation of all statins in human plasma. The mass spectrometry was conducted in negative ion electrospray mode for ROS determination and it showed retention time at 3.08 minutes and the lower concentration in the linearity range of 4 ng/mL. Abbreviations: HPTLC: high-performance thin-layer chromatography; TLC: thin-layer chromatography; UV: ultraviolet.
The ROS hepatic metabolism is negligible with low concentration of N-desmethyl metabolite (< 10% of parent drug) and 5S-lactone (12-24% of parent drug) product formed in hepatocytes. [129] Macwan et al. [120] developed and validated a sensitive method using LC-MS/MS in order to determine ROS and its metabolites in human plasma.
Other techniques for ROS quantification were also applied, including capillary zone electrophoresis, mercury drop electrode, highly sensitive enzyme-linked immunosorbent assay (ELISA), high-performance thin-layer chromatography (HPTLC), and TLC, as demonstrated in Table 5 . [54, [130] [131] [132] [133] [134] [135] [136] [137] [138] A microwell-based automated spectrophotometric method for determination of drugs using a colored charge-transfer (CT) complex has been developed as an alternative for the conventional spectrophotometric technique. [137] [138] [139] [140] This non-conventional spectrophotometric assay demonstrated advantages, such as automation, lower consumption of organic solvents, and relative sensitivity with the limit of quantification of 7.85 mg/well for the quantification of ROS. [138] Immunoassays have been widely used in pharmaceutical and clinical analysis of drugs. [141] [142] [143] [144] In this context, ROS analysis performed employing ELISA demonstrated high specificity and sensitivity with limit of detection at 40 pg/mL. [135] Other recent technique is the use of carbon nanotubes for the electroanalysis of drugs. A composite of vertically aligned carbon nanotubes and graphene oxide was used as the electrode material for the quantification of ROS in pharmaceutical and biological samples. [130] 
Conclusions
In this review, we have discussed the present state-of-the-art of spectrophotometric and chromatographic methods for the quantification of ROS in biological matrices and pharmaceutical formulations. Considering that ROS is a new statin approved in 2003, a considerable number of methods for its quantification are available. Spectrophotometric methods with UV-visible detection are particularly applied in ROS quantification in pharmaceutical formulations. Nevertheless, it is evident that HPLC-UV is the technique of choice for the quantification of ROS in biological matrices and pharmaceutical formulations. Further, LC-MS/MS methods is overcoming the HPLC-UV methods for the analysis of the ROS in biological fluids. The particular advantages of LC-MS/MS methods when compared with other techniques are selectivity and sensitivity with the quantification of ROS in the ng/mL range. 
